» Articles » PMID: 8221695

Coamplification of the CDK4 Gene with MDM2 and GLI in Human Sarcomas

Overview
Journal Cancer Res
Specialty Oncology
Date 1993 Nov 15
PMID 8221695
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

The 34-kilodalton cyclin-dependent kinase, p34cdk4, is a major catalytic subunit of mammalian D-type cyclins, which act during the G1 phase of the cell cycle to enforce the decision of cells to enter S phase. A murine complementary DNA clone was used to clone the cognate human CDK4 gene, which was localized to human chromosome 12, band q13, by fluorescence in situ hybridization. Because this chromosomal band contains the GLI and MDM2 genes, which are frequently amplified in human sarcomas, we analyzed CDK4 copy number and expression in a panel of sarcoma cell lines. An osteosarcoma cell line, OsACL, manifested a 25-fold increased copy number of CDK4, amplified concordantly with both GLI and MDM2, whereas a rhabdomyosarcoma cell line, SJRH30, was found to have an amplicon that included CDK4 and GLI but not MDM2. CDK4 mRNA and protein were overexpressed in both cell lines, and nucleotide sequencing analysis indicated that the gene had not sustained mutations. These observations provide the first evidence for amplification of a gene encoding a cell division cycle protein kinase, complement recent data indicating that genes encoding D-type cyclins are targets of chromosomal rearrangement and gene amplification in tumor cells, and suggest that CDK4 amplification might contribute to oncogenesis.

Citing Articles

CDK6 kinase inhibition unmasks metabolic dependencies in BCR::ABL1+ leukemia.

Scheiblecker L, Klampfl T, Doma E, Nebenfuehr S, Torres-Quesada O, Strich S Cell Death Dis. 2025; 16(1):107.

PMID: 39966356 PMC: 11836434. DOI: 10.1038/s41419-025-07434-1.


"GLI1 Subcellular Localization and Overexpression as Prognostic Factors for Disease-Free Survival in Colorectal Carcinoma".

Rather T, Parveiz I, Rashid G, Akhtar K, Mudassar S, Wani R J Gastrointest Cancer. 2024; 55(3):1359-1379.

PMID: 39018008 DOI: 10.1007/s12029-024-01090-y.


The value of GLI1 and p16 immunohistochemistry in the premolecular screening for GLI1-altered mesenchymal neoplasms.

Machado I, Agaimy A, Giner F, Navarro S, Michal M, Bridge J Virchows Arch. 2023; 484(5):765-775.

PMID: 37940743 PMC: 11694230. DOI: 10.1007/s00428-023-03687-3.


Integrated multi-omics analysis of RB-loss identifies widespread cellular programming and synthetic weaknesses.

Rajasekaran S, Siddiqui J, Rakijas J, Nicolay B, Lin C, Khan E Commun Biol. 2021; 4(1):977.

PMID: 34404904 PMC: 8371045. DOI: 10.1038/s42003-021-02495-2.


Advances of Targeted Therapy for Hepatocellular Carcinoma.

Niu M, Yi M, Li N, Wu K, Wu K Front Oncol. 2021; 11:719896.

PMID: 34381735 PMC: 8350567. DOI: 10.3389/fonc.2021.719896.